High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib

Introduction: Although treatment with osimertinib confers survival benefits in patients with lung cancer with the EGFR T790M mutation, the mechanism of acquired resistance to osimertinib remains poorly understood. We conducted a prospective observational study to identify the mechanism on the basis...

Full description

Bibliographic Details
Main Authors: Atsushi Osoegawa, MD, PhD, Masafumi Yamaguchi, MD, PhD, Tomomi Nakamura, MD, PhD, Ryotaro Morinaga, MD, Kentaro Tanaka, MD, PhD, Kosuke Kashiwabara, MD, PhD, Takashi Miura, MD, PhD, Takayuki Suetsugu, MD, PhD, Taishi Harada, MD, PhD, Tatsuma Asoh, MD, PhD, Kenichi Taguchi, MD, PhD, Kazuki Nabeshima, MD, PhD, Junji Kishimoto, MA, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kenji Sugio, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:JTO Clinical and Research Reports
Subjects:
Osimertinib
Targeted resequencing
Acquired resistance
EGFR T790M
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000503

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000503

Similar Items